Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis US20260098088A1
Summary
USPTO published patent application US20260098088A1 assigned to Disc Medicine, Inc. The application covers anti-hemojuvelin (HJV) antibodies and methods for treating myelofibrosis and associated conditions. Inventors include Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, and Jennifer M. Perez. CPC classifications include C07K 16/28 and related antibody technology classes.
What changed
USPTO published patent application US20260098088A1 for anti-HJV antibodies as a novel therapeutic approach for myelofibrosis treatment. The application discloses antibody compositions and methods of use by assignee Disc Medicine, Inc.
For pharmaceutical and biotechnology companies developing myelofibrosis treatments, this patent application signals competitive activity in the hemojuvelin pathway space. Entities pursuing similar therapeutic approaches should conduct freedom-to-operate analyses and consider potential patent landscape conflicts.
What to do next
- Monitor for updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
Application US20260098088A1 Kind: A1 Apr 09, 2026
Assignee
Disc Medicine, Inc.
Inventors
Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, Jennifer M. Perez
Abstract
Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
CPC Classifications
C07K 16/28 A61K 2039/505 C07K 2317/24 C07K 2317/565
Filing Date
2025-11-24
Application No.
19399067
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.